In the middle of the November gray and the gloomy lockdown light everyday life, the success message of the Mainz company Biontech and the US pharmaceutical company Pfizer for the development of a corona vaccine burst on Monday. There is hardly anything the world is currently waiting for as much as for effective protection against the virus. But as great as the joy of the impressive interim results of the western vaccine manufacturers is – many questions remain.
1What is known about BNT162b2
Biontech and Pfizer were the first western manufacturers to publish the results of a study that was crucial for approval on Monday. Accordingly, your vaccine offers more than 90 percent protection against the disease Covid-19. Serious side effects have not yet been registered, it said. The companies expected to apply for approval from the US FDA starting next week.
Biontech had been developing the BNT162b2 vaccine in the “Lightspeed” project since mid-January. The phase 3 study, which is crucial for approval, began in late July. By Monday, more than 43,500 people had received at least one of the two vaccinations, which are given every three weeks. According to the manufacturer, vaccination protection is achieved one week after the second injection.